Paper
0
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Authors
Isabelle Ray‐Coquard,Patricia Pautier
Sandro Pignata,David Pérol,Antonio González-Martı́n,Regina Berger,Keiichi Fujiwara,Ignace Vergote,Nicoletta Colombo,Johanna Mäenpää,Frédèric Selle,Jalid Sehouli,Domenica Lorusso,Eva Alía,Alexander Reinthaller,Shoji Nagao,Claudia Lefeuvre‐Plesse,Ulrich Canzler,Giovanni Scambia,Alain Lortholary,Frederik Marmé,Pierre Combe,Nikolaus Gregorio,Manuel Rodrigues,Paul Buderath,Coraline Dubot,Alexander Burges,Benoît You,Éric Pujade-Lauraine,Philipp Harter
+28 authors
,Antonio González‐MartínPublished
Dec 18, 2019
Show more
Save
Tip0
TipSave
Abstract
Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of combining maintenance olaparib and bevacizumab in patients regardless of BRCA mutation status is unknown.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.